Innovent eyes third-line nod for gastric cancer ADC on Phase III PFS hit

Innovent's ADC is currently under priority review by China’s NMPA, which could see it join the country’s third-line gastric cancer market. The CLDN18.2-targeting asset is currently under priority review by China’s NMPA, which could see it join the country’s third-line gastric cancer market. Innovent’s CLN18.2-targeting ADC, arcotatug tavatecan, is currently under review by Chinese drug regulators in G/GEJ. Credit: Forhad_505 / Shutterstock.com. Takeda’s $11.4bn bet on assets from Chinese biotech, Innovent Biologics, is showing early signs of paying off, as the latter is seeking the regulatory go-ahead for its gastric cancer asset, arcotatug tavatecan, on home turf following a Phase…

Source: Clinical Trials Arena